Our strategy going forward

The full marketing authorization of Pepaxti in Europe is the foundation for Oncopeptides’ strategy and enables us to give patients with multiple myeloma access to an innovative drug, that may reduce treatment burden and improve quality of life. In addition to European sales, Oncopeptides has identified a number of next step value drivers that will drive the company into the future: sales of Pepaxti outside of Europe and the company’s innovation pipeline.

A growing subset of the patients with multiple myeloma are triple class refractory. Their disease has become refractory to the three major drug classes. There is a clear unmet need, particular in elderly patients who need accessible treatments. Our strategy is supporting the company’s vision “bringing hope through science”, and is built on five pillars.

Financial discipline

We aspire to ensure that the company has a long-term, sustainable cash and equity position until the company becomes financially self-sufficient. In addition to sales, we are heavily focused on optimizing cost by focusing on activities that maximize patient and shareholder value.

European launch

We aspire to ensure that physicians and payors prefer Pepaxti in elderly patients with relapsed, refractory multiple myeloma. We are launching Pepaxti with a patient-focused team, determined to bring new science to the benefit of the right patients. The team is well networked, has in-depth scientific knowledge, strong business acumen and drives scientific share of voice and advocacy.

Geographic expansion

We continuously analyze the market situation and develop our strategy market access strategy based on it. Outside of Europe, China and Japan are currently the most viable markets and the company is currently looking at opportunities to either license Pepaxti or form a partnership there.

Pipeline progression

We aspire to progress the development of drug candidates for difficult to treat cancer diseases with significant unmet medical needs.

The drug candidates are based on the proprietary Peptide Drug Conjugate platform, PDC, and the SPiKEs platform (Small Polypeptide based Killer Engagers). For SPiKE, the first candidate selection will take place early in 2024 and for PDC, the first drug Pepaxti is already commercialized while next generation PDC development is in an early stage.

People and culture

We aspire to build company engagement and attraction through our vision and values. We act with an enterprise spirit and believe that the journey to becoming a strong company brand starts internally. We strive to attract, retain and develop key talents in the industry.